Last reviewed · How we verify
NCT05827510
Fractional Radiofrequency for Treatment of Acne Scars and Wrinkles
NA trial testing BTL-585F in Acne in 31 participants. Completed in 10 December 2021.
1 September 2021
Quick facts
| Lead sponsor | BTL Industries Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 30 November 2020 |
| Primary completion | 1 September 2021 |
| Estimated completion | 10 December 2021 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- BTL-585F
Conditions studied
Sponsor
BTL Industries Ltd. — full company profile →
Who can join
21 and older, any sex, with Acne or Wrinkle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the clinical efficacy, safety and the performance of the fractional radiofrequency delivered by the BTL-585-4 applicator of the BTL-585F system for non-invasive treatment of acne scars and facial wrinkles. The study is a prospective multicenter open label two-arm study. The subjects will be enrolled and assigned into two study groups, according to their indication; group A (acne scars) and B (facial wrinkles), each study group will receive treatment of different conditions. Subjects of both groups will be required to complete three (3) treatment visits and two to three follow-up visits.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05827510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acne
Currently open trials in the same condition.
- NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
- NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
- NCT06989840 — Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne · Phase 1 · recruiting
- NCT07368764 — The Suitability of Tience® for Treating Acne Scars · NA · recruiting
- NCT06909344 — 577-nm Diode Laser in the Treatment of Non -Inflammatory Acne · NA · recruiting
Other BTL Industries Ltd. trials
Trials by the same sponsor.
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07179224 — EEG Changes After rTMS Stimulation · NA · completed
- NCT07024550 — Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway · NA · active not recruiting
- NCT07027657 — EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05827510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BTL Industries Ltd.
- Last refreshed: 2 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05827510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing